Vision Possible: Why Eyestem Is ‘Bullish’ About Its Dry AMD Candidate

Citeline Podcasts

English - November 30, 2022 07:15 - 29 minutes - 11.1 MB - ★★★★★ - 24 ratings
Business News Business News Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Digital Health Roundup: HLTH2022 Highlights, EU Updates, Diabetes Medtech Monthly

Next Episode: Scrip’s Five Must-Know Things – 5 December 2022

Eyestem’s founder and CEO, Dr Jogin Desai, talks to Scrip about progress made by the firm’s experimental treatment for dry age-related macular degeneration, cell and gene therapy pricing considerations and the wider competitive landscape. The company is also developing treatments for retinitis pigmentosa and idiopathic pulmonary fibrosis.